JUO3 Rec'd PCT/PTO 01 APR 2005

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE REV. 12-2004) ATTORNEY'S DOCKET NUMBER **PU4959USW** TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) 5301 CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE October 3, 2002 September 24, 2003 PCT/US2003/30334 TITLE OF INVENTION Therapeutic Compounds Based on Pyrazolopyridine Derivatives APPLICANT(S) FOR DO/EO/US GUDMUNDSSON, Kristjan, S.; JOHNS, Brian, A. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. `⊠ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. 4. The US has been elected (Article 31). \boxtimes 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. 🗆 has been communicated by the International Bureau. c. 🛛 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🛚 is attached hereto. b. 🔲 has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. 🔲 are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. c. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. d. 🔯 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). \boxtimes An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10 П An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. \boxtimes 15. A FIRST preliminary amendment. Ō 16. A SECOND or SUBSEQUENT preliminary amendment. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). \boxtimes 22. Express Mail Label No. EV 332063977 US 23. X Other items or information: a) PCT Cover Page b) PCT Request

JC13 Rec'd PCT/PTO 01 APR 2005

PTO-1390 (Rev. 12-2004)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)			INTERNATIONAL APPLICATION NO.				ATTORNEY'S DOCKET NUMBER	
10/530101		PCT/US20	PCT/US2003/30334			PU4959USW		
24. The following	g fees are submitte	ed:				L	Applicant use	Office use
🖾 a) Basic nat	ional fee				\$300.	00	\$ \$300.00	
🛛 b) Examina							\$ \$200.00	
⊠ c) Search fee						00	\$ \$500.00	
TOTAL OF ABOVE CALCULATIONS = \$1000.00						oo	\$ \$1,000.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						31,000.00		
Total Sheets	Extra Sheets	Number	mber of each additional 50 or RATE on thereof (round up to a whole					
- 100 =	/50 =				× \$250.0	00	\$ \$0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).							\$	
CLAIMS	NUMBER F		NUMBER EXTRA		RATE			
Total claims	22	- 20 =	2	х	\$50.0	0	\$ \$100.00	
Independent clair	ns 2	- 3=	0	x	\$200.0	0	\$ \$0.00	,
MULTIPLE DEPE	NDENT CLAIMS	(if applicable) 🗆	+	\$360.0	0	\$ \$0.00	
		TOT	AL OF ABOVE CA	LC	ULATIONS	s =	\$ \$1,100.00	
Applicant cla		atus. See 37	CFR 1.27. The fees in	ndica	ted above are	е	\$ \$0.00	
,				S	UBTOTAL	L = T	\$ \$1,100.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						n .	\$ \$0.00	
TOTAL NATIONAL FEE =						E =	\$ \$1,100.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						+	\$ \$0.00	
TOTAL FEES ENCLOSED = \$ \$1,100.00								
Amount to be refunded:						ed:		\$
Amount to be charged:							\$	
a. A check	in the amount of \$		to cover the a	bove	fees is enclo	sed.		
b. 🗵 Please o	harge my Deposit ate copy of this sho	Account No. eet is	07-1392 ii	n the	amount of	9	61,100.00 to cove	er the above fees.
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1392 . A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:								
-)		SIGNAT	URE		
Lorie Ann						Ann I	Morgan	
23347 NAME								
38,181								
					RATI	TION NUMBER		

10/530101

			10/220107			
CERTIFICATE OF Applicant(s): Gudmund	MAILING BY "EXPRESS sson et al.	MAIL" (37 GFR 3-Rec'd PCT	/PTO DOG KIET APPR 2005 PU4959USW			
Serial No. To Be Assigned	Filing Date Concurrently Herewith	Examiner	Group Art Unit			
Invention: Therapeutic	Compounds Based on Pyrazolop	pyridine Derivatives				
	e following correspondence:	nying papers				
	(Identify typ	e of correspondence)				
	h the United States Postal Serv	vice "Express Mail Post Office to Add er for Patents, P.O. Box 1450, Alexai				
·	(=)	77 1 1 4 T TO 1111 .				
		Valerie L. Phillip (Typed or Printed Name of Person Mailin				
		Villeri Milly (Signature of Person Mailing Corf)	espondence)			
		2U77PE405EEV3				
		("Express mun muning Luver				